A New Perspective on the Heterogeneity of Cancer Glycolysis

Simple item page
dc.contributor.authorNeugent, Michael L.en_US
dc.contributor.authorGoodwin, Justinen_US
dc.contributor.authorSankaranarayanan, Ishwaryaen_US
dc.contributor.authorYetkin, Celal Emreen_US
dc.contributor.authorHsieh, Meng-Hsiungen_US
dc.contributor.authorKim, Jung-whanen_US
dc.contributor.utdAuthorNeugent, Michael L.en_US
dc.contributor.utdAuthorSankaranarayanan, Ishwaryaen_US
dc.contributor.utdAuthorYetkin, Celal Emreen_US
dc.contributor.utdAuthorHsieh, Meng-Hsiungen_US
dc.contributor.utdAuthorKim, Jung-whanen_US
dc.date.accessioned2018-10-22T20:06:00Z
dc.date.available2018-10-22T20:06:00Z
dc.date.created2017-12-07en_US
dc.date.issued2018-10-22
dc.description.abstractTumors are dynamic metabolic systems which highly augmented metabolic fluxes and nutrient needs to support cellular proliferation and physiological function. For many years, a central hallmark of tumor metabolism has emphasized a uniformly elevated aerobic glycolysis as a critical feature of tumorigenecity. This led to extensive efforts of targeting glycolysis in human cancers. However, clinical attempts to target glycolysis and glucose metabolism have proven to be challenging. Recent advancements revealing a high degree of metabolic heterogeneity and plasticity embedded among various human cancers may paint a new picture of metabolic targeting for cancer therapies with a renewed interest in glucose metabolism. In this review, we will discuss diverse oncogenic and molecular alterations that drive distinct and heterogeneous glucose metabolism in cancers. We will also discuss a new perspective on how aberrantly altered glycolysis in response to oncogenic signaling is further influenced and remodeled by dynamic metabolic interaction with surrounding tumor-associated stromal cells.en_US
dc.description.departmentSchool of Natural Sciences and Mathematicsen_US
dc.description.sponsorship"Our original work is partially supported by the National Cancer Institute (NCI) of the National Institute of Health (NIH), CA208746 and American Lung Association, LCD-400239."en_US
dc.identifier.bibliographicCitationNeugent, Michael L., Justin Goodwin, Ishwarya Sankaranarayanan, Celal Emre Yetkin, et al. 2018; 2018; 2018. "A new perspective on the heterogeneity of cancer glycolysis." Biomolecules & Therapeutics 26(1), 10-18, doi:10.4062/biomolther.2017.210en_US
dc.identifier.issue1en_US
dc.identifier.urihttp://hdl.handle.net/10735.1/6235
dc.identifier.volume26en_US
dc.language.isoenen_US
dc.relation.urihttp://dx.doi.org/10.4062/biomolther.2017.210
dc.rightsCC BY-NC 4.0/ (Attribution-NonCommercial)en_US
dc.rights©2018 The Korean Society of Applied Pharmacologyen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/en_US
dc.sourceBiomolecules & Therapeutics
dc.subjectCanceren_US
dc.subjectGlycolysisen_US
dc.subjectMetabolismen_US
dc.subjectStromal Cellsen_US
dc.subjectTumor Microenvironmenten_US
dc.titleA New Perspective on the Heterogeneity of Cancer Glycolysisen_US
dc.type.genrearticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
NSM-5621-8458.23.pdf
Size:
4.7 MB
Format:
Adobe Portable Document Format
Description:
Article
Download

Collections

Kim, Jung-whan